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Collagen (Col) VI is a major component of the extracellular matrix which, in skel-
etal muscle, is localized just outside the basement membrane. Defi ciency of ColVI in 
humans due to mutations of COL6 genes gives rise to Bethlem Myopathy (BM), Ull-
rich Congenital Muscular Dystrophy (UCMD), and Myosclerosis Myopathy. About 70 
diff erent COL6 gene  mutations have been associated to ColVI myopathies which, 
although present  a wide range of clinical features, share a common pathogenesis. 
This mechanism, initially identifi ed in the Col6a1-/- model (Irwin et al., 2003), and 
then in cultures from BM and UCMD patients (Angelin et al., 2007), involves a mito-
chondrial dysfunction due to deregulation of the permeability transition pore (PTP). 
The pathogenic role of PTP opening, causing the release of proapoptotic factors, has 
been confi rmed by the normalizing eff ect of cyclosporine A (CsA) on  the mitochon-
drial defect and on the increased apoptotic rate in both the mouse model and in a 
selected group of patients (Merlini et al., 2008).
We have recently demonstrated that the persistence of abnormal mitochondria 
and apoptosis are amplifi ed by defective autophagy (Grumati et al., 2010). In fact, 
forced activation of autophagy by genetic, dietary and pharmacological approaches 
restore myofi ber survival and ameliorate the dystrophic phenotype in mice. Since 
also muscle cells of BM and UCMD patients  present a defective activation of the 
autophagic machinery, it will be possible to restore this activity by using  a low pro-
tein diet or drugs capable to reactivate autophagy.
To monitor the eff ects of therapies on ColVI-related myopathies highly inva-
sive muscle/skin biopsies have been so far utilized. We have recently obtained evi-
dence that ColVI expression in blood macrophages from BM and UCMD patients can 
be detected at levels comparable to those observed in muscle biopsies and cultured 
skin fi broblasts (Gualandi et al., 2011). These data support the suitability of peripheral 
blood macrophages as a reliable, minimally invasive tool for supplementing or replac-
ing highly invasive biopsies in the diagnosis and monitoring of ColVI myopathies.
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